AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Please note
: Importing new articles from Word documents is currently unavailable. We are working on fixing this issue soon and apologize for any inconvenience.
Kenny Vo
Public Documents
1
The novel use of emapalumab and ruxolitinib in acquired malignancy-associated hemopha...
Kenny Vo
and 2 more
July 22, 2021
Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal syndrome of immune dysregulation that is classified into primary and secondary forms. The standard of care is established with dexamethasone and etoposide, but there are currently no guidelines for refractory HLH or cases triggered by infection or malignancy. [1] We describe here a series of pediatric patients with malignancy-associated HLH (m-HLH) to discuss the complexities in the initial diagnostic considerations, the balance of therapeutic regimens and their toxicities, and the novel use of emapalumab and ruxolitinib in patients with refractory disease.